دورية أكاديمية
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries
| العنوان: | Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries |
|---|---|
| المؤلفون: | Cortellini, Alessio, Dettorre, Gino M, Dafni, Urania, Aguilar-Company, Juan, Castelo-Branco, Luis, Lambertini, Matteo, Gennatas, Spyridon, Angelis, Vasileios, Sita-Lumsden, Ailsa, Rogado, Jacobo, Pedrazzoli, Paolo, Viñal, David, Prat, Aleix, Rossi, Maura, Berardi, Rossana, Alonso-Gordoa, Teresa, Grisanti, Salvatore, Dimopoulou, Georgia, Queirolo, Paola, Pradervand, Sylvain, Bertuzzi, Alexia, Bower, Mark, Arnold, Dirk, Salazar, Ramon, Tucci, Marco, Harrington, Kevin J, Mazzoni, Francesca, Mukherjee, Uma, Tsourti, Zoi, Michielin, Olivier, Pommeret, Fanny, Brunet, Joan, Vincenzi, Bruno, Tonini, Giuseppe, Patriarca, Andrea, Biello, Federica, Krengli, Marco, Tabernero, Josep, Pentheroudakis, George, Gennari, Alessandra, Peters, Solange, Romano, Emanuela, Pinato, David J |
| المساهمون: | Cortellini, Alessio, Dettorre, Gino M, Dafni, Urania, Aguilar-Company, Juan, Castelo-Branco, Lui, Lambertini, Matteo, Gennatas, Spyridon, Angelis, Vasileio, Sita-Lumsden, Ailsa, Rogado, Jacobo, Pedrazzoli, Paolo, Viñal, David, Prat, Aleix, Rossi, Maura, Berardi, Rossana, Alonso-Gordoa, Teresa, Grisanti, Salvatore, Dimopoulou, Georgia, Queirolo, Paola, Pradervand, Sylvain, Bertuzzi, Alexia, Bower, Mark, Arnold, Dirk, Salazar, Ramon, Tucci, Marco, Harrington, Kevin J, Mazzoni, Francesca, Mukherjee, Uma, Tsourti, Zoi, Michielin, Olivier, Pommeret, Fanny, Brunet, Joan, Vincenzi, Bruno, Tonini, Giuseppe, Patriarca, Andrea, Biello, Federica, Krengli, Marco, Tabernero, Josep, Pentheroudakis, George, Gennari, Alessandra, Peters, Solange, Romano, Emanuela, Pinato, David J |
| سنة النشر: | 2022 |
| المجموعة: | IRIS UNIPV (Università degli studi di Pavia) |
| مصطلحات موضوعية: | COVID-19, Cytotoxicity, Immunologic, Immunogenicity, Vaccine, Immunotherapy, Vaccination |
| الوصف: | BackgroundAs management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer.MethodsIn a joint analysis of ICI recipients from OnCovid (NCT04393974) and European Society for Medical Oncology (ESMO) CoCARE registries, we assessed severity and mortality from SARS-CoV-2 in vaccinated and unvaccinated patients with cancer and explored whether prior immune-related adverse events (irAEs) influenced outcome from COVID-19.FindingsThe study population consisted of 240 patients diagnosed with COVID-19 between January 2020 and February 2022 exposed to ICI within 3 months prior to COVID-19 diagnosis, with a 30-day case fatality rate (CFR30) of 23.6% (95% CI 17.8 to 30.7%). Overall, 42 (17.5%) were fully vaccinated prior to COVID-19 and experienced decreased CFR30 (4.8% vs 28.1%, p=0.0009), hospitalization rate (27.5% vs 63.2%, p<0.0001), requirement of oxygen therapy (15.8% vs 41.5%, p=0.0030), COVID-19 complication rate (11.9% vs 34.6%, p=0.0040), with a reduced need for COVID-19-specific therapy (26.3% vs 57.9%, p=0.0004) compared with unvaccinated patients. Inverse probability of treatment weighting (IPTW)-fitted multivariable analysis, following a clustered-robust correction for the data source (OnCovid vs ESMO CoCARE), confirmed that vaccinated patients experienced a decreased risk of death at 30 days (adjusted OR, aOR 0.08, 95% CI 0.01 to 0.69).Overall, 38 patients (15.8%) experienced at least one irAE of any grade at any time prior to COVID-19, at a median time of 3.2 months (range 0.13-48.7) from COVID-19 diagnosis. IrAEs occurred independently of baseline characteristics except for primary tumor (p=0.0373) and were associated with a significantly decreased CFR30 (10.8% vs 26.0%, p=0.0462) additionally confirmed by the IPTW-fitted multivariable analysis (aOR 0.47, 95% CI 0.33 to 0.67). Patients who experienced irAEs also presented a higher median absolute lymphocyte count at COVID-19 ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36450384; info:eu-repo/semantics/altIdentifier/wos/WOS:000895435200006; volume:10; issue:11; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; https://hdl.handle.net/11571/1477577Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85143102641 |
| DOI: | 10.1136/jitc-2022-005732 |
| الإتاحة: | https://doi.org/10.1136/jitc-2022-005732Test https://hdl.handle.net/11571/1477577Test |
| رقم الانضمام: | edsbas.DA5B2D19 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/jitc-2022-005732 |
|---|